Physician profile
William B Campbell
NPI 1902069156
$2,967.22
in general payments reported to CMS, 2019-2025
37 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $203 · 2021: $706 · 2022: $478 · 2023: $430 · 2024: $494 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $816.03 | 2019-2024 | Lo Loestrin Fe, Orilissa |
| Hologic Sales and Service, LLC | $198.29 | 2021-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Organon LLC | $189.56 | 2021-2025 | Nexplanon |
| Optumhealth Care Solutions, LLC | $188.94 | 2023-2025 | Vivify Health Care Team Portal, Eitan Medical, Vivify Health Care Team Portal 001 |
| Avion Pharmaceuticals | $118.46 | 2019-2022 | |
| Sage Therapeutics, LLC | $115.67 | 2021-2025 | Zurzuvae |
| Allergan, INC. | $110.83 | 2021 | |
| Novo Nordisk INC | $102.59 | 2021-2024 | Wegovy, Saxenda |
| Astellas Pharma US INC | $98.07 | 2019-2025 | Veozah |
| Intuitive Surgical, INC. | $85.49 | 2024 | |
| Daiichi Sankyo INC. | $81.25 | 2019-2024 | Injectafer |
| Therapeuticsmd, INC. | $81.16 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.41 | 2020-2025 | |
| Pfizer INC. | $75.09 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $71.45 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $65.00 | 2022 | |
| Agile Therapeutics, INC. | $62.20 | 2022 | |
| Minerva Surgical, INC | $60.22 | 2023-2024 | |
| Meditrina | $38.20 | 2023 | |
| Exeltis, USA INC. | $37.30 | 2022-2025 | Slynd |
| Shield Therapeutics INC | $37.20 | 2023-2025 | Accrufer |
| Amag Pharmaceuticals, INC. | $26.98 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $25.59 | 2024 | |
| Solventum Corporation | $19.67 | 2024 | Prevena |
| Takeda Pharmaceuticals U.S.A., INC. | $18.03 | 2021 | |
| Mylan Pharmaceuticals INC. | $16.44 | 2021 | |
| Sumitomo Pharma America, INC. | $15.97 | 2025 | Myfembree |
| Boston Scientific Corporation | $15.54 | 2024 | |
| Kci USA, INC. | $15.15 | 2023 | Prevena |
| Innovation Technologies INC | $14.88 | 2025 | Irrisept |
| Mayne Pharma Commercial LLC | $13.89 | 2021 | |
| Ethicon US, LLC | $13.16 | 2019 | |
| Evofem Biosciences, INC. | $12.93 | 2021 | |
| Covidien LP | $12.67 | 2019 | |
| Horizon Therapeutics Plc | $12.67 | 2020 | |
| Virtus Pharmaceuticals LLC | $12.23 | 2021 | |
| Lupin INC. | $12.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.